http://www.law360.com/ Latest articles for organization: Ranbaxy Laboratories Copyright 2009 Portfolio Media, Inc. en-US http://www.law360.com/images/headings/logo.gif http://www.law360.com/ http://www.law360.com/articles/130249 Roche Palo Alto LLC has decided to appeal a ruling that while its patent for Valcyte is valid, a generic version of the anti-viral drug made by Ranbaxy Laboratories Ltd. does not infringe it. http://www.law360.com/articles/130249 http://www.law360.com/articles/126896 Impax Laboratories Inc. has reached an agreement with drugmakers Astellas Pharma Inc. and Boehringer Ingelheim Pharmaceuticals Inc. to settle a patent dispute related to a generic version of Flomax, a drug used to treat the symptoms of an enlarged prostate. http://www.law360.com/articles/126896 http://www.law360.com/articles/125567 A judge has ruled that a Roche Palo Alto LLC patent used for the formulation of its anti-viral drug Valcyte is valid but that Ranbaxy Laboratories Ltd.’s generic version of the drug does not infringe it. http://www.law360.com/articles/125567 http://www.law360.com/articles/124883 Eisai Co. Ltd. has asked a federal court to dismiss Apotex Inc.’s declaratory judgment action over four patents covering Eisai’s Alzheimer’s drug Aricept, arguing that Apotex is using the suit to try to jump ahead of competitors in the approval process to market the generic drug. http://www.law360.com/articles/124883 http://www.law360.com/articles/121510 A federal judge has dismissed a declaratory judgment suit filed by Teva Pharmaceuticals Inc. and its Gate Pharmaceuticals division seeking a determination that they did not infringe four patents covering Eisai Co. Ltd.'s blockbuster Alzheimer's drug Aricept. http://www.law360.com/articles/121510 http://www.law360.com/articles/119939 Cephalon Inc. has asked a federal judge to dismiss the Federal Trade Commission's ongoing antitrust suit alleging that the drugmaker illegally paid off generics competitors in a reverse payment agreement over the patent for narcolepsy drug Provigil. http://www.law360.com/articles/119939 http://www.law360.com/articles/119788 Walgreen Co., Safeway Inc. and three others have become the latest retailers to accuse Cephalon Inc. of striking illegal deals with generic-drug makers to keep a copycat version of narcolepsy drug Provigil off the market. http://www.law360.com/articles/119788 http://www.law360.com/articles/117780 Pharmacy chains including Rite Aid Corp. and CVS Caremark Corp. have waded into the antitrust litigation against Cephalon Inc., filing a complaint over the pharmaceutical company's alleged conspiracy with generics makers to keep narcolepsy drug Provigil off the market. http://www.law360.com/articles/117780 http://www.law360.com/articles/116207 Orchid Chemicals & Pharmaceuticals Ltd. and its subsidiary Orgenus Pharma Inc. have reached an agreement with Schering-Plough Corp. that will allow Orchid to bring two generic versions of Schering's allergy drug Clarinex to the U.S. market in 2012. http://www.law360.com/articles/116207 http://www.law360.com/articles/113704 A judge on Tuesday asked for all motions to be refiled in the Federal Trade Commission's ongoing antitrust suit alleging Cephalon Inc. paid off generic competitors in the market for its narcolepsy drug Provigil. http://www.law360.com/articles/113704 http://www.law360.com/articles/109472 Canadian generics maker Apotex Inc. has fired off a declaratory judgment action asserting it is not infringing Eisai Co. Ltd.’s patents, in a move to secure federal approval for its generic version of the Tokyo company’s Alzheimer’s drug Aricept. http://www.law360.com/articles/109472 http://www.law360.com/articles/103278 The defense of inequitable conduct needs reform, as the standard for proving the defense is perceived by many in the patent bar as being applied somewhat inconsistently right now at the Federal Circuit, says Joseph M. O’Malley Jr., chair of Paul Hastings Janofsky & Walker LLP's intellectual property practice. http://www.law360.com/articles/103278 http://www.law360.com/articles/107808 Sen. Bill Nelson, D-Fla., has introduced legislation in the U.S. Senate to revise the Hatch-Waxman Act's definition of “first applicant” for abbreviated new drug application filers to give generic-drug makers challenging brand-name patents a shot at receiving 180-day market exclusivity. http://www.law360.com/articles/107808 http://www.law360.com/articles/106581 Pfizer Inc. has filed an infringement lawsuit against Mylan Inc., accusing the generic-drug maker of trying to market and sell generic versions of the blockbuster anti-cholesterol drug Lipitor before the expiration of the drug giant's patents. http://www.law360.com/articles/106581 http://www.law360.com/articles/106149 In its ongoing bid to protect Solodyn from generic competitors, skin health specialist Medicis Pharmaceutical Corp. has accused Indian generics maker Ranbaxy Laboratories Ltd. of infringing a patent for the popular acne medication. http://www.law360.com/articles/106149 http://www.law360.com/articles/90507 Though the priorities of the Federal Trade Commission under President Obama's administration are not yet clear, Chairman Jon Leibowitz's dissents and concurrences over the last several years suggest that he will take the agency in a more aggressive, pro-consumer direction on several fronts. http://www.law360.com/articles/90507 http://www.law360.com/articles/102647 A federal judge has handed down a claim construction order for one of the patents in Sanofi-Aventis’ multidistrict litigation alleging Mylan Pharmaceuticals Inc. and other generic-drug manufacturers have infringed its technology covering its prostate treatment, Uroxatral. http://www.law360.com/articles/102647 http://www.law360.com/articles/102202 In two cases over a patent related to Abbott Laboratories' bacterial infection drug Omnicef, an appeals court has ruled that defining a product in a patent by the process through which it is made limits the scope of infringement that can be determined. http://www.law360.com/articles/102202 http://www.law360.com/articles/96026 Mylan Pharmaceuticals Inc. and Schering Corp. have reached an agreement in patent litigation over Clarinex that will allow the generics maker to begin selling a copycat version of the allergy medicine in July 2012. http://www.law360.com/articles/96026 http://www.law360.com/articles/90553 As Merck & Co. prepares to join forces with Schering-Plough Co. in a $41.1 billion deal, the drugmaker stands ready to inherit a host of legal problems — including antitrust, employment, intellectual property and product liability suits — right along with an expanded arsenal of drugs and medical technology. http://www.law360.com/articles/90553